BioAge Labs Inc. (BIOA)
BIOA Stock Price Chart
Explore BioAge Labs Inc. interactive price chart. Choose custom timeframes to analyze BIOA price movements and trends.
BIOA Company Profile
Discover essential business fundamentals and corporate details for BioAge Labs Inc. (BIOA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
26 Sept 2024
Employees
61.00
Website
https://bioagelabs.comCEO
Kristen Fortney
Description
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
BIOA Financial Timeline
Browse a chronological timeline of BioAge Labs Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 Aug 2026
EPS estimate is -$0.65, while revenue estimate is $1.46m.
Earnings released on 8 May 2026
EPS came in at -$0.52 surpassing the estimated -$0.64 by +18.70%, while revenue for the quarter reached $2.77m , beating expectations by +155.88%.
Earnings released on 24 Mar 2026
EPS came in at -$0.72 surpassing the estimated -$0.83 by +13.25%, while revenue for the quarter reached $3.08m , beating expectations by +119.86%.
Earnings released on 6 Nov 2025
EPS came in at -$0.56 surpassing the estimated -$0.67 by +16.42%, while revenue for the quarter reached $2.05m , beating expectations by +80.18%.
Earnings released on 6 Aug 2025
EPS came in at -$0.60 falling short of the estimated -$0.56 by -7.14%, while revenue for the quarter reached $2.41m , beating expectations by +177.24%.
Earnings released on 6 May 2025
EPS came in at -$0.36 surpassing the estimated -$0.52 by +30.77%, while revenue for the quarter reached $1.45m , beating expectations by +150.17%.
Earnings released on 20 Mar 2025
EPS came in at -$1.97 falling short of the estimated -$0.58 by -239.66%.
Earnings released on 7 Nov 2024
EPS came in at -$6.70 falling short of the estimated -$0.72 by -830.56%.
Earnings released on 26 Sept 2024
EPS came in at -$1.80 .
Earnings released on 31 Mar 2024
EPS came in at -$1.74 .
Earnings released on 31 Dec 2023
EPS came in at -$2.81 .
Earnings released on 30 Sept 2023
EPS came in at -$1.96 .
Earnings released on 30 Jun 2023
EPS came in at -$2.30 .
Earnings released on 31 Mar 2023
EPS came in at -$1.48 .
BIOA Stock Performance
Access detailed BIOA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
